Monday, 30 January 2023


The Consortium

The NeoVanc Consortium has been specifically structured to include the principal individuals and networks conducting research and clinical trials in the optimal treatment in neonatal infection. The NeoVanc Consortium has been defined by merging the expertise in PENTA-ID running the NeoMero trial and The Infections in Neonates Network, running TINN1 and TINN 2. Other members of the consortium include the Italian Neonatal Network with extensive experience in neonatal clinical trials.

The following main criteria guided the composition of the Consortium:
  1. Complementarity in expertise and resources: The Consortium should harbour specific complementary expertise and/or resources necessary for the successful completion of the tasks planned in the proposal.
  2. Direct links to clinical sites for patients’ recruitment: The Consortium should have the clinical expertise and experience in clinical research in NICU. They also should be able to enrol the number of patients needed for the planned clinical trials.
  3. Direct links to external stakeholders: The Consortium should have a strategic position in research on paediatric medicine, including links with EMEA, European scientific societies (e.g. ESPID) and other relevant European networks (e.g. PENTA, GRIP, TINN, ARPEC).
  4. Balanced geographical spread: Globally, the Consortium should have a balanced geographical spread, should be kept manageable and efficient.
  5. Efficiency: Because the activities in NeoVanc are in part complementary to the existing coordination activities in PENTA-ID, significant efficiencies can be achieved if use is made of the existing resources, infrastructures and data present in the PENTA-ID network. This would allow the Consortium participants to work together in a simplified and efficient manner that only could be assured by a solid administrative and technical structure set up to manage international research projects.

Copyright © NeoVanc | All rights reserved. Read the disclaimer.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041
Privacy policy | Terms and conditions